What is Hua Medicine (Shanghai) Ltd. (HUMDF) stock price today?

Hua Medicine (Shanghai) Ltd. (HUMDF) is currently trading at $0.31, up 0% today.

What is HUMDF P/E ratio?

Hua Medicine (Shanghai) Ltd.'s P/E ratio is 1.91. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HUMDF return on equity (ROE)?

Hua Medicine (Shanghai) Ltd.'s return on equity (ROE) is 107.22%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Hua Medicine (Shanghai) Ltd.'s market cap?

Hua Medicine (Shanghai) Ltd. has a market capitalization of $313.26M.

OTC · Drug Manufacturers - Specialty & Generic

Hua Medicine (Shanghai) Ltd. (HUMDF) Stock

$0.31 +0.00% OTC: HUMDF Healthcare

Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market.

Valuation

Metric	Value
Price	$0.31
Market Cap	$313.26M
P/E Ratio	1.91
P/B Ratio	2.27
P/S Ratio	4.41
EPS (TTM)	$0.16
52-Week High	$0.50
52-Week Low	$0.31
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	107.22%
ROA	75.33%
ROCE	-11.39%
Gross Margin	56.85%
Operating Margin	-29.40%
Net Margin	226.82%
Debt/Equity	0.30
Current Ratio	6.17

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$18.0M	$77.0M	$256.0M	$480.0M
Operating Profit	$-321.0M	$-267.0M	$-289.0M	$-353.0M	$-141.0M
Net Profit	$-331.0M	$-204.0M	$-211.0M	$-250.0M	$1.1B
EPS	$-0.34	$-0.21	$-0.22	$-0.25	$1.10
Op Margin	—	-1517.8%	-377.4%	-137.8%	-29.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$904.0M	$1.1B	$1.7B	$1.5B	$1.5B
Total Liabilities	$453.0M	$842.0M	$1.6B	$1.7B	$464.0M
Cash	$675.0M	$491.0M	$1.5B	$1.1B	$1.1B
Borrowings	$72.0M	$98.0M	$168.0M	$300.0M	$302.0M

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-273.0M	$-230.0M	$889.0M	$-418.0M	$-52.0M
Investing Cash Flow	$-135.0M	$-32.0M	$-2.0M	$6.0M	$-8.0M
Financing Cash Flow	$-16.0M	$0	$-31.0M	$-31.0M	$-28.0M
Net Cash Flow	$-357.0M	$-185.0M	$970.0M	$-321.0M	$-47.0M
Free Cash Flow	$-340.0M	$-258.0M	$880.0M	$-422.0M	$-60.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-11.24
FCF Yield	-2.56%
Quick Ratio	5.59
Interest Coverage	-34.94
Return 1Y	-23.46%
Return 3Y	55.00%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About Hua Medicine (Shanghai) Ltd.

Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's disease, and for the management of both late-stage Type 2 and Type 1 Diabetes. Furthermore, Hua Medicine is also progressing mGLUR5, an investigational treatment targeting levodopa-induced dyskinesia in Parkinson's disease. Established in 2011, the company's operations are headquartered in Beijing, China.

Hua Medicine (Shanghai) Ltd. is headquartered in CN.

Hua Medicine (Shanghai) Ltd. (HUMDF) stock trades at $0.31 with a market capitalization of $313.26M. The stock is valued at a price-to-earnings (P/E) ratio of 1.91, price-to-book of 2.27, price-to-sales of 4.41. Over the past 52 weeks the stock has ranged between $0.31 and $0.50, and currently trades 38.0% below its 52-week high.

On profitability, Hua Medicine (Shanghai) Ltd. generates a return on equity (ROE) of 107.22% — well above the market average, a sign of a high-quality business, return on capital employed of -11.39%, an operating margin of -29.40%, a net profit margin of 226.82%.

Official website: www.huamedicine.com